New Injectable Drug Could Treat Esophagitis Symptoms
A Phase III study found TEZSPIRE reduced inflammation and improved swallowing for adults with eosinophilic esophagitis.
Updated on Oct. 29, 2026 in Asthma
Live Poll
Do you trust that new pharmaceutical treatments will provide better relief for chronic health conditions?
The Phase III CROSSING trial shows that TEZSPIRE, an injectable treatment, significantly reduces esophageal inflammation and swallowing difficulties in patients with eosinophilic esophagitis. The findings, presented in October 2026, suggest a potential new therapeutic option for those managing the condition.
Why it matters
Eosinophilic esophagitis causes persistent inflammation and difficulty swallowing, significantly impacting daily nutrition and quality of life. This trial provides evidence that targeting specific immune pathways could offer a new approach to managing the condition when current treatments are insufficient.
In the Phase III CROSSING trial, researchers observed significant histologic remission in patients receiving TEZSPIRE versus placebo at 24 and 52 weeks. Long-term efficacy and safety remain under evaluation.
The players
AstraZeneca
A global pharmaceutical company focused on oncology, rare diseases, and immune-mediated conditions like asthma.
Amgen
A biotechnology company known for developing therapies for inflammation, oncology, and bone health.
The details
TEZSPIRE is a subcutaneous injection administered every four weeks that functions by blocking thymic stromal lymphopoietin, a protein involved in immune-mediated inflammation. By inhibiting this pathway, the drug aims to reduce the underlying allergic-type response that triggers tissue damage in the esophagus. Participants in the study were permitted to maintain stable background treatments with proton pump inhibitors or topical corticosteroids, providing insight into how the drug may integrate with current management protocols.
Timeline
Week 24 served as the initial assessment point for histologic remission and swallowing symptom improvement.
Week 52 marked the conclusion of long-term monitoring for endoscopic and histologic outcomes.
Findings were presented in October 2026 at United European Gastroenterology Week.
Health Landscape
This development represents a strategic expansion of TEZSPIRE into the treatment of eosinophilic esophagitis, moving beyond its established role in inflammatory respiratory disease. It reflects a broader trend of repurposing monoclonal antibody therapies to address diverse immune-mediated conditions.
These results offer a glimpse into a potential future treatment for those struggling with the symptoms of eosinophilic esophagitis. Any decision regarding the suitability of emerging biologic therapies should be discussed with a gastroenterologist or immunologist who manages your specific care.
The takeaway
The CROSSING trial results highlight how immune-targeting biologics may improve tissue health and swallowing function in eosinophilic esophagitis. If you have been diagnosed with this condition, consider keeping a symptom log to share with your specialist during your next routine checkup.
Further reading
For more information on the management of chronic inflammatory conditions, visit our Asthma section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust that new pharmaceutical treatments will provide better relief for chronic health conditions?
